Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Graft Versus Host Disease (GVHD) Overview 11 Therapeutics Development 12 Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 12 Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 13 Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 14 Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 18 Graft Versus Host Disease (GVHD) - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Graft Versus Host Disease (GVHD) - Products under Development by Companies 23 Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 27 Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 28 AbbVie Inc. 28 AbGenomics International, Inc. 29 Actelion Ltd 30 Alexion Pharmaceuticals, Inc. 31 Apceth GmbH & Co. KG 32 arGEN-X BV 33 Athersys, Inc. 34 Bellicum Pharmaceuticals, Inc. 35 Bio-Cancer Treatment International Limited 36 Biogen, Inc. 37 Bristol-Myers Squibb Company 38 Caladrius Biosciences, Inc. 39 Cantex Pharmaceuticals, Inc. 40 Cell2B S.A. 41 CellECT Bio, Inc. 42 Cynata Therapeutics Limited 43 Cytodyn Inc. 44 Dr. Falk Pharma GmbH 45 Effimune SAS 46 Escape Therapeutics, Inc. 47 F. Hoffmann-La Roche Ltd. 48 Fate Therapeutics, Inc. 49 Generon (Shanghai) Corporation Ltd. 50 GlaxoSmithKline Plc 51 Idera Pharmaceuticals, Inc. 52 ImmuNext, Inc. 53 Immunomedics, Inc. 54 Incyte Corporation 55 Kadmon Corporation, LLC 56 Kamada Ltd. 57 Kiadis Pharma B.V. 58 Kymab Limited 59 Kyorin Pharmaceutical Co., Ltd. 60 MacroGenics, Inc. 61 Mallinckrodt Plc 62 Medsenic 63 Mesoblast Limited 64 Millennium Pharmaceuticals, Inc. 65 Neopharm Ltd. 66 Novartis AG 67 OncoImmune, Inc. 68 Pharmicell Co., Ltd. 69 REGiMMUNE Corporation 70 Rigel Pharmaceuticals, Inc. 71 Sarepta Therapeutics, Inc. 72 Seattle Genetics, Inc. 73 Seres Therapeutics, Inc. 74 Sigmoid Pharma Limited 75 Spherium Biomed S.L. 76 Targazyme, Inc. 77 Therapix Biosciences Ltd 78 Tobira Therapeutics, Inc. 79 Xenikos B.V. 80 ZIOPHARM Oncology, Inc. 81 Graft Versus Host Disease (GVHD) - Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Combination Products 83 Assessment by Target 84 Assessment by Mechanism of Action 88 Assessment by Route of Administration 91 Assessment by Molecule Type 93 Drug Profiles 95 abatacept - Drug Profile 95 AbGn-168H - Drug Profile 98 aldesleukin - Drug Profile 99 Alecmestencel-L - Drug Profile 101 alpha-1 proteinase inhibitor (human) - Drug Profile 102 ALXN-1007 - Drug Profile 104 anti-thymocyte globulin (rabbit) - Drug Profile 105 Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 107 Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 108 ARGX-115 - Drug Profile 109 arsenic trioxide - Drug Profile 110 ATIR-101 - Drug Profile 111 BCT-200 - Drug Profile 113 begelomab - Drug Profile 114 Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 115 Biologics for Graft Versus Host Disease - Drug Profile 116 bortezomib - Drug Profile 117 BPX-501 - Drug Profile 123 brentuximab vedotin - Drug Profile 125 budesonide - Drug Profile 132 cannabidiol - Drug Profile 135 CD-24Fc - Drug Profile 137 Cellgram for Graft Versus Host Disease - Drug Profile 138 Cellular Immunotherapy for Autoimmune Diseases and GVHD - Drug Profile 139 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 141 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 142 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 143 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 144 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 145 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 146 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 147 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 148 Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 149 cenicriviroc mesylate - Drug Profile 150 CLBS-03 - Drug Profile 152 CRCBT-080004 - Drug Profile 153 CX-01 - Drug Profile 154 cyclosporine CR + cyclosporine IR - Drug Profile 156 CYP-001 - Drug Profile 157 F-652 - Drug Profile 158 FR-104 - Drug Profile 159 Ha-7 - Drug Profile 161 ibrutinib - Drug Profile 162 ImmuneSafe - Drug Profile 170 IMO-8400 - Drug Profile 172 IT-603 - Drug Profile 174 IT-901 - Drug Profile 175 itacitinib adipate - Drug Profile 176 KD-025 - Drug Profile 178 KRP-203 - Drug Profile 180 KY-1005 - Drug Profile 182 MAX-16H5 - Drug Profile 183 MesoStem - Drug Profile 184 methoxsalen - Drug Profile 185 MGD-010 - Drug Profile 187 milatuzumab - Drug Profile 189 Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 191 natalizumab - Drug Profile 193 OCU-300 - Drug Profile 195 Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 196 panobinostat - Drug Profile 197 PF-05285401 - Drug Profile 204 ponesimod - Drug Profile 209 Preimplantation Factor - Drug Profile 211 PRO-140 - Drug Profile 213 ProTmune - Drug Profile 218 Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders - Drug Profile 219 Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 220 Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 221 remestemcel-L - Drug Profile 222 RGI-2001 - Drug Profile 226 RO-2959 - Drug Profile 228 SER-155 - Drug Profile 229 Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders - Drug Profile 230 Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders - Drug Profile 231 Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile 232 Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 233 sonidegib phosphate - Drug Profile 234 SP-12008 - Drug Profile 238 Substance X - Drug Profile 239 SYGN-305G - Drug Profile 240 T-Guard - Drug Profile 241 TZ-101 - Drug Profile 243 ZL-1101 - Drug Profile 245 Graft Versus Host Disease (GVHD) - Recent Pipeline Updates 246 Graft Versus Host Disease (GVHD) - Dormant Projects 347 Graft Versus Host Disease (GVHD) - Discontinued Products 352 Graft Versus Host Disease (GVHD) - Product Development Milestones 353 Featured News & Press Releases 353 Appendix 360 Methodology 360 Coverage 360 Secondary Research 360 Primary Research 360 Expert Panel Validation 360 Contact Us 360 Disclaimer 361

List of Tables Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2016 18 Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Development by Companies, H1 2016 (Contd..1) 21 Number of Products under Development by Companies, H1 2016 (Contd..2) 22 Number of Products under Development by Companies, H1 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Late Stage Development, H1 2016 25 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Development, H1 2016 27 Comparative Analysis by Unknown Stage Development, H1 2016 28 Products under Development by Companies, H1 2016 29 Products under Development by Companies, H1 2016 (Contd..1) 30 Products under Development by Companies, H1 2016 (Contd..2) 31 Products under Development by Companies, H1 2016 (Contd..3) 32 Products under Investigation by Universities/Institutes, H1 2016 33 Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc., H1 2016 34 Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H1 2016 35 Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H1 2016 36 Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 37 Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H1 2016 38 Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H1 2016 39 Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H1 2016 40 Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 41 Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 42 Graft Versus Host Disease (GVHD) - Pipeline by Biogen, Inc., H1 2016 43 Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H1 2016 44 Graft Versus Host Disease (GVHD) - Pipeline by Caladrius Biosciences, Inc. , H1 2016 45 Graft Versus Host Disease (GVHD) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 46 Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H1 2016 47 Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio, Inc., H1 2016 48 Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Limited, H1 2016 49 Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc., H1 2016 50 Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H1 2016 51 Graft Versus Host Disease (GVHD) - Pipeline by Effimune SAS, H1 2016 52 Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H1 2016 53 Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 54 Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics, Inc., H1 2016 55 Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2016 56 Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H1 2016 57 Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 58 Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H1 2016 59 Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H1 2016 60 Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corporation, H1 2016 61 Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H1 2016 62 Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H1 2016 63 Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma B.V., H1 2016 64 Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H1 2016 65 Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 66 Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H1 2016 67 Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H1 2016 68 Graft Versus Host Disease (GVHD) - Pipeline by Medsenic, H1 2016 69 Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H1 2016 70 Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 71 Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H1 2016 72 Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H1 2016 73 Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune, Inc., H1 2016 74 Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H1 2016 75 Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H1 2016 76 Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 77 Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H1 2016 78 Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H1 2016 79 Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics, Inc., H1 2016 80 Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H1 2016 81 Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H1 2016 82 Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H1 2016 83 Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd, H1 2016 84 Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H1 2016 85 Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H1 2016 86 Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology, Inc., H1 2016 87 Assessment by Monotherapy Products, H1 2016 88 Assessment by Combination Products, H1 2016 89 Number of Products by Stage and Target, H1 2016 91 Number of Products by Stage and Mechanism of Action, H1 2016 95 Number of Products by Stage and Route of Administration, H1 2016 98 Number of Products by Stage and Molecule Type, H1 2016 100 Graft Versus Host Disease (GVHD) Therapeutics - Recent Pipeline Updates, H1 2016 252 Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2016 353 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H1 2016 354 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H1 2016 355 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H1 2016 356 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..4), H1 2016 357 Graft Versus Host Disease (GVHD) - Discontinued Products, H1 2016 358 List of Figures Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2016 18 Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Products, H1 2016 27 Assessment by Monotherapy Products, H1 2016 88 Number of Products by Top 10 Targets, H1 2016 90 Number of Products by Stage and Top 10 Targets, H1 2016 90 Number of Products by Top 10 Mechanism of Actions, H1 2016 94 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 94 Number of Products by Routes of Administration, H1 2016 97 Number of Products by Stage and Routes of Administration, H1 2016 97 Number of Products by Molecule Types, H1 2016 99 Number of Products by Stage and Molecule Types, H1 2016 99

AbbVie Inc. AbGenomics International, Inc. Actelion Ltd Alexion Pharmaceuticals, Inc. Apceth GmbH & Co. KG arGEN-X BV Athersys, Inc. Bellicum Pharmaceuticals, Inc. Bio-Cancer Treatment International Limited Biogen, Inc. Bristol-Myers Squibb Company Caladrius Biosciences, Inc. Cantex Pharmaceuticals, Inc. Cell2B S.A. CellECT Bio, Inc. Cynata Therapeutics Limited Cytodyn Inc. Dr. Falk Pharma GmbH Effimune SAS Escape Therapeutics, Inc. F. Hoffmann-La Roche Ltd. Fate Therapeutics, Inc. Generon (Shanghai) Corporation Ltd. GlaxoSmithKline Plc Idera Pharmaceuticals, Inc. ImmuNext, Inc. Immunomedics, Inc. Incyte Corporation Kadmon Corporation, LLC Kamada Ltd. Kiadis Pharma B.V. Kymab Limited Kyorin Pharmaceutical Co., Ltd. MacroGenics, Inc. Mallinckrodt Plc Medsenic Mesoblast Limited Millennium Pharmaceuticals, Inc. Neopharm Ltd. Novartis AG OncoImmune, Inc. Pharmicell Co., Ltd. REGiMMUNE Corporation Rigel Pharmaceuticals, Inc. Sarepta Therapeutics, Inc. Seattle Genetics, Inc. Seres Therapeutics, Inc. Sigmoid Pharma Limited Spherium Biomed S.L. Targazyme, Inc. Therapix Biosciences Ltd Tobira Therapeutics, Inc. Xenikos B.V. ZIOPHARM Oncology, Inc.